<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02219113</url>
  </required_header>
  <id_info>
    <org_study_id>RU-CCH-03-02-14</org_study_id>
    <nct_id>NCT02219113</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Autologous ADRC for Treatment of Degenerative Damage of Knee Articular Cartilage</brief_title>
  <official_title>Effectiveness and Safety of Intraarticular Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Degenerative Damage of Knee Articular Cartilage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>I.M. Sechenov First Moscow State Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autologous adipose-derived regenerative cells (ADRC) extracted using Celution 800/CRS System&#xD;
      (Cytori Therapeutics Inc) from a portion of the fat harvested from the patient's front&#xD;
      abdominal wall. ADRC will be administered one-time intraarticularly. This is a single arm&#xD;
      study with no control. All patients receive cell therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with verified diagnosis knee joint osteoarthritis (degenerative damage of knee&#xD;
      articular cartilage) will undergo knee arthroscopic debridement. 28 days later patients will&#xD;
      will undergo liposuction from front abdominal wall under local anesthesia. After that&#xD;
      autologous ADRC will be extracted using Celution 800/CRS System (Cytori Therapeutics Inc)&#xD;
      from harvested adipose tissue. Extracted ADRC will be administered one-time intraarticularly.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of serious adverse events (SAEs) and serious adverse reactions (SARs)</measure>
    <time_frame>4 weeks after treatment</time_frame>
    <description>Types, probability and severity of treatment emergent serious adverse events (SAEs) and serious adverse reactions (SARs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life monitoring</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Quality of life estimated by validated questionnaires: the Short Form (36) Health Survey (SF-36), Knee Injury and Osteoarthritis Outcome Score (KOOS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee pain intensity monitoring</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Knee pain intensity assessed by Visual Analogue Scale (no pain=0; maximum pain=100 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in knee joint structures</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Changes in knee joint structure assessed by:&#xD;
X-ray (joint space width, bone contour, presence of osteophytes and sclerosis);&#xD;
MRI (articular cartilage, osteophytes, bone marrow abnormality, meniscal integrity, synovial effusion/tissue, anterior and posterior cruciate ligaments, and medial and lateral collateral ligaments);&#xD;
Ultrasonography (effusion, synovial thickening or hypertrophy, cartilage parameters, vascularity, Baker's cysts, osteophytes, tendon and ligament abnormalities, meniscal changes, bursitis, erosions and panniculitis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in knee function</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Changes in knee function assessed by validated questionnaire: Knee Society Score (KSS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Knee Joint Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>ADRC injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected intraarticularly into knee joint.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Arthroscopic surgery</intervention_name>
    <arm_group_label>ADRC injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liposuction</intervention_name>
    <arm_group_label>ADRC injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ADRC isolation</intervention_name>
    <description>ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol</description>
    <arm_group_label>ADRC injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intraarticular administration of autologous ADRC</intervention_name>
    <arm_group_label>ADRC injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pain in the knee joint during more than a half day assessed by VAS (score more than 40&#xD;
             mm)&#xD;
&#xD;
          -  At least three of the following 6 criteria: 50 years of age or older, stiffness&#xD;
             lasting less than 30 minutes, crepitus, bony tenderness, bony enlargement, no warmth&#xD;
             to the touch&#xD;
&#xD;
          -  Patient is able to walk without assistance&#xD;
&#xD;
          -  Patient is familiar with Participant information sheet&#xD;
&#xD;
          -  Patient signed informed consent form&#xD;
&#xD;
        Non-inclusion Criteria:&#xD;
&#xD;
          -  Medical history of endoprosthetic knee replacement&#xD;
&#xD;
          -  Medical history of lower extremity osteotomy&#xD;
&#xD;
          -  Medical history of knee surgery (including arthroscopy) during preceding 1 year prior&#xD;
             to enrollment&#xD;
&#xD;
          -  Medical history of intraarticular injections during preceding 6 months prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Secondary osteoarthritis of the knee joint: posttraumatic osteoarthritis (developed&#xD;
             after clinically significant injury), intra-articular fractures, clinically&#xD;
             significant varus or valgus deformities of lower limbs, septic arthritis, joint's&#xD;
             inflammatory disorders, gout, advanced chondrocalcinosis, Paget's disease, ochronosis,&#xD;
             acromegaly, hemochromatosis, Wilson's disease, primary synovial osteochondromatosis,&#xD;
             osteonecrosis, hemophilia&#xD;
&#xD;
          -  Patients prescribed for immunosuppressive treatment&#xD;
&#xD;
          -  Medical history of systemic autoimmune and inflammatory diseases&#xD;
&#xD;
          -  Significant weight loss (&gt; 10% of body weight in the previous year) of unknown&#xD;
             etiology&#xD;
&#xD;
          -  Medical history of venous thromboembolism or estimated high risk of venous&#xD;
             thromboembolism&#xD;
&#xD;
          -  Patients prescribed for systemic corticosteroids or other medications treatment with&#xD;
             proven impact on bone or cartilage tissue metabolism&#xD;
&#xD;
          -  Clinically significant abnormalities in results of laboratory tests&#xD;
&#xD;
          -  Any conditions limiting compliance (dementia, neuropsychiatric disease, drug and&#xD;
             alcohol abuse etc.)&#xD;
&#xD;
          -  Participation in other clinical trials (or administration of investigational drugs)&#xD;
             during 3 months prior inclusion&#xD;
&#xD;
          -  Patients with malignant tumors including postoperative period, patients receiving&#xD;
             chemotherapy and/or radiotherapy.&#xD;
&#xD;
          -  Patient's activated partial thromboplastin time exceeds normal levels more than 1,8&#xD;
             times&#xD;
&#xD;
          -  Patients prescribed for anticoagulants treatment or patient received anticoagulants at&#xD;
             least one hour prior lipoaspiration&#xD;
&#xD;
          -  Medical history of heterotopic ossifications&#xD;
&#xD;
          -  Patients prescribed for glycoprotein inhibitors treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient's refusal from the further participation in trial&#xD;
&#xD;
          -  Patient's refusal from compliance with the requirements of contraception during the&#xD;
             participation in research&#xD;
&#xD;
          -  Chronic kidney disease IV- V stages (creatinine clearance &lt; 30 mL/min estimated by&#xD;
             Cockroft-Gault formula)&#xD;
&#xD;
          -  Confirmed syphilis, HIV, hepatitis B or C infections&#xD;
&#xD;
        Dropout Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey V Ivannikov, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>I.M. Sechenov First Moscow State Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ilya I Eremin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Budgetary Institution &quot;Central Clinical Hospital with Outpatient Health Center&quot; of the Business Administration for the President of the Russian Federation; Center for Biomedical Technologies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;Central Clinical Hospital with Outpatient Health Center&quot; of the Business Administration for the President of the Russian Federation; Center for Biomedical Technologies</name>
      <address>
        <city>Moscow</city>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>August 15, 2014</study_first_submitted>
  <study_first_submitted_qc>August 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2014</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Damage of articular cartilage</keyword>
  <keyword>Cartilage degeneration</keyword>
  <keyword>Intraarticular injection</keyword>
  <keyword>ADRC</keyword>
  <keyword>Adipose-derived regenerative cells</keyword>
  <keyword>Adipose tissue</keyword>
  <keyword>Stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

